LINC00237: LINC00237 is a novel long non-coding RNA (lncRNA) gene that has been implicated in various diseases and conditions. In MOMO syndrome, a rare genetic disorder, the balanced reciprocal translocation disrupts LINC00237 [PMC6884712]. LINC00237 has been found to have a positive correlation with overall survival in certain conditions [PMC8798494]. It is located at the breakpoint on chromosome 20p11.23 in MOMO syndrome patients [PMC4848934]. The expression of LINC00237 is reduced in patients' lymphoblasts compared to control individuals [PMC4848934]. In tumor progression, LINC00237 is one of the downregulated lncRNAs [PMC5802034]. It has also been associated with better overall survival in patients with low-grade gliomas (LGG) [PMC7390977]. Furthermore, LINC00237 expression is downregulated in gliomas and upregulated in WHO grade III gliomas [PMC7390977]. In various cancer types, including uterine corpus endometrial carcinoma (UCEC) and pancreatic ductal adenocarcinoma (PDAC), high expression of LINC00237 has been associated with longer survival time [PMC9988759] [PMC9601640]. The precise molecular function of LINC00237 remains to be determined, but it may be involved in necroptosis-related processes and self-renewal of tumor initiating cells by promoting stability of β-catenin [PMC9988759] [PMC7470401]. Additionally, it has been implicated in genetic disorders such as BPES and MOMO syndrome but its exact role remains unknown [PMC5502309] Finally, the expression of AL596188.1 and LINC00237 has been positively correlated with overall survival in certain conditions[ PMC9857477].